Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1203pxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 27	OCT 07	Multiple databases enhanced for more flexible patent number searching

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:33:28 ON 07 OCT 2008

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:33:36 ON 07 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 OCT 2008  HIGHEST RN 1057750-28-3
DICTIONARY FILE UPDATES:   6 OCT 2008  HIGHEST RN 1057750-28-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10846978.str
```





chain nodes :
10 17 24
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 18 19 20 21 22 23
chain bonds :
1-11 5-18 8-10 12-17 21-24
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
2-7 3-9 5-18 7-8 8-9 18-19 18-23 19-20 20-21 21-22 22-23
exact bonds :
1-11 8-10 12-17 21-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 full
FULL SEARCH INITIATED 14:33:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      307 TO ITERATE

100.0% PROCESSED      307 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

L2            4 SEA SSS FUL L1

=> file medline caplus wpids
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     178.57

FILE 'MEDLINE' ENTERED AT 14:34:09 ON 07 OCT 2008

FILE 'CAPLUS' ENTERED AT 14:34:09 ON 07 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:34:09 ON 07 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

=> s l2
SAMPLE SEARCH INITIATED 14:34:13 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED        1 ITERATIONS                                1 ANSWERS
```

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 40
PROJECTED ANSWERS: 1 TO 40

L3 35 L2

=> s l3 and (nausea or vomit? or emesis)
L4 6 L3 AND (NAUSEA OR VOMIT? OR EMESIS)

=> d l4 1-6 ibib, abs, hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:771031 CAPLUS
DOCUMENT NUMBER: 149:104693
TITLE: Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition and their preparation
INVENTOR(S): Lange, Josephus H. M.; Kruse, Cornelis G.; Shadid, Belal
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
SOURCE: PCT Int. Appl., 48pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2008074816	A1	20080626	WO 2007-EP64169		20071219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080153867	A1	20080626	US 2007-957948		20071217
PRIORITY APPLN. INFO.:			EP 2006-126584	A	20061220
			US 2006-875808P	P	20061220
OTHER SOURCE(S):	MARPAT 149:104693				

GI



II

AB This invention concerns compds. of formula I [I = A-(T)n-B, wherein A is essential structural element of known CB1 antagonist; T is a (un)saturated linear carbon liner; B is essential structural element of known acetylcholinesterase inhibitor; N is 0 and 1] with a combination of cannabinoid-CB1 antagonism and cholinesterase inhibition, to pharmaceutical compns. containing these compds., to methods for preparing the compds., methods for preparing intermediates useful for their synthesis, and methods for preparing compns. The invention also relates to the uses of such compds. and compns., particularly for treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficits, traumatic brain injury, drug dependence, addiction and substance abuse. Compds. of formula II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their CB1 antagonistic activity and their acetylcholinesterase inhibitory activity.

IT 99487-26-0DP, MCI-225, pharmacophoric element, conjugates with CB1 antagonist pharmacophoric element
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of compds. with both CB1 receptor antagonistic and acetylcholinesterase inhibiting activities)

RN 99487-26-0 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1243410 CAPLUS
DOCUMENT NUMBER: 147:491675
TITLE: Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine for dosage forms
INVENTOR(S): Cooper, Martin Ian; Frampton, Christopher Stephen
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 49pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070254891	A1	20071101	US 2007-728947	20070327
WO 2008051282	A2	20080502	WO 2007-US7816	20070327
WO 2008051282	A3	20080731		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-788338P P 20060331
US 2006-808603P P 20060526

AB The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride (MCI-225) crystalline forms. The present invention is also directed to compns. including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders. Thus, maturation study of MCI-225 was carried out using a diverse set of 25 solvents chosen based on their dielec. constant, dipole moment and functionality. In general, the neat solvents gave Form II and the solvents with 5% water added gave Form I of MCI-225. However, there were one or two exceptions. In neat hexane, toluene, cumene and tetraline, measurements showed either Form I alone or a mixture with Form II. Without wishing to be bound by any particular theory, it is believed that this may be due to low or very low solubility of the compound in these solvents. In isopropanol (IPA), NMP, MeOH, DMF and DMSO with 5% water, measurements showed only Form II. These materials were generally highly crystalline and most were suitable for single crystal work. Again, without wishing to be bound by any particular theory, it is believed that, because Form I is a 1:1 hydrate, solns. with a higher activity of water will have a greater tendency to produce Form I. Also, MCI-225 caused a significant dose-dependent increase in bladder capacity following acetic acid irritation in cats, with individual dose significance attained at the 30 mg/kg dose. These data supported the initial pos. findings in the rat, demonstrating that MCI-225 was effective in increasing bladder capacity in commonly utilized models of overactive

bladder in two species. These results were also predictive of the efficacy of MCI-225 in the treatment of benign prostatic hyperplasia (BPH), for example, the irritative symptoms of BPH.

IT 99487-25-9D, salts 99487-26-0, MCI-225
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable crystalline forms of 4-(2-fluorophenyl)-6-Me-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts for dosage forms)

RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-26-0 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1204654 CAPLUS
DOCUMENT NUMBER: 147:462326
TITLE: Soluble salts of thieno[2,3-d]pyrimidine derivatives, and therapeutic use
INVENTOR(S): Cooper, Martin Ian
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 80pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2007120445 A1 20071025 WO 2007-US7633 20070327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
US 20070254899 A1 20071101 US 2007-728966 20070327
PRIORITY APPLN. INFO.: US 2006-788565P P 20060331
US 2006-808905P P 20060526

OTHER SOURCE(S): MARPAT 147:462326

AB The invention discloses salts of thieno[2,3-d]pyrimidine derivs., including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The invention also discloses compns. including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

IT 99487-26-0, MCI-225
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-26-0 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9D, salts
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



IT 99487-25-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(soluble salts of thienopyrimidine derivs., and therapeutic use)
RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1030476 CAPLUS
DOCUMENT NUMBER: 145:389426
TITLE: Method of treating disorders and conditions using peripherally restricted 5-HT3 antagonists and inhibitors
INVENTOR(S): Thor, Karl Bruce; Ricca, Daniel J.
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 129pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006105117	A2	20061005	WO 2006-US11334	20060327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20060293309 A1 20061228 US 2006-389887 20060327

PRIORITY APPLN. INFO.: US 2005-666253P P 20050328

OTHER SOURCE(S): MARPAT 145:389426

AB The invention features compds., e.g. 5-HT3 receptor antagonists, having a peripherally restricted mode of action such that the compds. affect 5-HT3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compds. are particularly useful in treating disorders or conditions ameliorated by antagonism of peripheral 5-HT3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT3 receptors can be lessened or reduced using the peripherally restricted compds. of the invention. Compds. of the invention are quaternary ammonium derivs. of MCI-225. Compound preparation is included.

IT 99487-26-0D, MCI 225, quaternary ammonium derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)

RN 99487-26-0 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)

RN 99487-25-9 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:610068 CAPLUS
DOCUMENT NUMBER: 141:134099
TITLE: Method of treating nausea, vomiting , or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor
INVENTOR(S): Landau, Steven B.; Miller, Cheryl L.; Thor, Karl Bruce
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062624	A2	20040729	WO 2004-US809	20040113
WO 2004062624	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204827	A1	20040729	AU 2004-204827	20040113
AU 2004204827	B2	20060629		
CA 2512022	A1	20040729	CA 2004-2512022	20040113
US 20040147510	A1	20040729	US 2004-757981	20040113
EP 1567163	A2	20050831	EP 2004-701830	20040113
EP 1567163	B1	20070411		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006748	A	20051220	BR 2004-6748	20040113
CN 1750827	A	20060322	CN 2004-80004249	20040113
JP 2006516977	T	20060713	JP 2006-500937	20040113
AT 359079	T	20070515	AT 2004-701830	20040113
NZ 541009	A	20070928	NZ 2004-541009	20040113
ES 2285407	T3	20071116	ES 2004-701830	20040113
US 20040254171	A1	20041216	US 2004-846978	20040514
US 20040254172	A1	20041216	US 2004-846979	20040514
US 7094786	B2	20060822		
IN 2005DN02961	A	20070413	IN 2005-DN2961	20050704
MX 2005PA07379	A	20060210	MX 2005-PA7379	20050707
ZA 2005005816	A	20060927	ZA 2005-5816	20050720
PRIORITY APPLN. INFO.:			US 2003-440076P P	20030113
			US 2003-492478P P	20030804
			US 2004-757981 A1	20040113
			WO 2004-US809 W	20040113

OTHER SOURCE(S): MARPAT 141:134099

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount In addition, the method of the invention comprises administering a NARI alone. A pharmaceutical composition comprising: (a) a first amount of a 5-HT3 receptor antagonist; and (b) a second amount of a noradrenaline reuptake inhibitor is

also claimed.
IT 99487-25-9 99487-25-9D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)
RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:203673 CAPLUS
DOCUMENT NUMBER: 140:229481
TITLE: New therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine
INVENTOR(S): Cavalla, David; Gristwood, Robert William
PATENT ASSIGNEE(S): Arachnova Therapeutics Ltd., UK
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019948	A1	20040311	WO 2003-GB3720	20030828

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2496695	A1	20040311	CA 2003-2496695		20030828
AU 2003259373	A1	20040319	AU 2003-259373		20030828
AU 2003259373	B2	20060309			
EP 1539172	A1	20050615	EP 2003-791032		20030828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013836	A	20050621	BR 2003-13836		20030828
CN 1678322	A	20051005	CN 2003-820617		20030828
JP 2006500427	T	20060105	JP 2004-569724		20030828
US 20060167005	A1	20060727	US 2005-525532		20050725
PRIORITY APPLN. INFO.:			GB 2002-20064	A	20020829
			GB 2003-16115	A	20030709
			WO 2003-GB3720	W	20030828

AB 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain, and other conditions.

IT 99487-25-9 476148-82-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine)

RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 476148-82-0 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H_2O

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:33:28 ON 07 OCT 2008)

FILE 'REGISTRY' ENTERED AT 14:33:36 ON 07 OCT 2008
L1 STRUCTURE UPLOADED
L2 4 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS' ENTERED AT 14:34:09 ON 07 OCT 2008
L3 35 S L2
L4 6 S L3 AND (NAUSEA OR VOMIT? OR EMESIS)

=> s l3 and (cancer or tumor)
L5 0 L3 AND (CANCER OR TUMOR)

=> s l3 and chemotherap?
L6 6 L3 AND CHEMOTHERAP?

=> d l6 1-6 ibib, abs, hitstr

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:771031 CAPLUS
DOCUMENT NUMBER: 149:104693
TITLE: Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition and their preparation
INVENTOR(S): Lange, Josephus H. M.; Kruse, Cornelis G.; Shadid, Belal
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
SOURCE: PCT Int. Appl., 48pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008074816	A1	20080626	WO 2007-EP64169	20071219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080153867	A1	20080626	US 2007-957948	20071217
PRIORITY APPLN. INFO.:			EP 2006-126584 A	20061220
			US 2006-875808P P	20061220

OTHER SOURCE(S): MARPAT 149:104693

GI



II

AB This invention concerns compds. of formula I [I = A-(T)n-B, wherein A is essential structural element of known CB1 antagonist; T is a (un)saturated linear carbon liner; B is essential structural element of known acetylcholinesterase inhibitor; N is 0 and 1] with a combination of cannabinoid-CB1 antagonism and cholinesterase inhibition, to pharmaceutical compns. containing these compds., to methods for preparing the compds., methods for preparing intermediates useful for their synthesis, and methods for preparing compns. The invention also relates to the uses of such compds. and compns., particularly for treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficits, traumatic brain injury, drug dependence, addiction and substance abuse. Compds. of formula II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their CB1 antagonistic activity and their acetylcholinesterase inhibitory activity.

IT 99487-26-0DP, MCI-225, pharmacophoric element, conjugates with CB1 antagonist pharmacophoric element

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of compds. with both CB1 receptor antagonistic and acetylcholinesterase inhibiting activities)

RN 99487-26-0 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1030476 CAPLUS
DOCUMENT NUMBER: 145:389426
TITLE: Method of treating disorders and conditions using peripherally restricted 5-HT3 antagonists and inhibitors
INVENTOR(S): Thor, Karl Bruce; Ricca, Daniel J.
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 129pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006105117	A2	20061005	WO 2006-US11334	20060327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060293309	A1	20061228	US 2006-389887	20060327
PRIORITY APPLN. INFO.:			US 2005-666253P P	20050328
OTHER SOURCE(S):		MARPAT 145:389426		

AB The invention features compds., e.g. 5-HT3 receptor antagonists, having a peripherally restricted mode of action such that the compds. affect 5-HT3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compds. are particularly useful in treating disorders or conditions ameliorated by antagonism of

peripheral 5-HT3 receptors. Moreover, side-effects attributable to antagonism of central 5-HT3 receptors can be lessened or reduced using the peripherally restricted compds. of the invention. Compds. of the invention are quaternary ammonium derivs. of MCI-225. Compound preparation is included.

IT 99487-26-0D, MCI 225, quaternary ammonium derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)

RN 99487-26-0 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 99487-25-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(MCI-225 quaternary ammonium derivative peripherally restricted 5-HT3 antagonists for treatment of disorders and conditions)

RN 99487-25-9 CAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:878266 CAPLUS
DOCUMENT NUMBER: 141:343543
TITLE: Method of treating lower urinary tract disorders with 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor combination
INVENTOR(S): Landau, Steven B.; Miller, Cheryl L.; Fraser, Matthew O.
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089288	A2	20041021	WO 2004-US10088	20040402
WO 2004089288	A3	20050421		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004227945	A1	20041021	AU 2004-227945	20040402
AU 2004227945	B2	20061026		
CA 2519379	A1	20041021	CA 2004-2519379	20040402
US 20040209869	A1	20041021	US 2004-817332	20040402
US 6846823	B2	20050125		
EP 1539181	A2	20050615	EP 2004-758741	20040402
EP 1539181	B1	20070627		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522144	T	20060928	JP 2006-509595	20040402
EP 1795196	A2	20070613	EP 2007-5612	20040402
EP 1795196	A3	20080206		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 365554	T	20070715	AT 2004-758741	20040402
ES 2290741	T3	20080216	ES 2004-758741	20040402
US 20050020577	A1	20050127	US 2004-863771	20040607
US 20050026909	A1	20050203	US 2004-863770	20040607
US 7115606	B2	20061003		
US 20050272719	A1	20051208	US 2005-122940	20050504
US 20050282799	A1	20051222	US 2005-124580	20050506
AU 2007200317	A1	20070215	AU 2007-200317	20070125

PRIORITY APPLN. INFO.:			
US 2003-461022P	P	20030404	
US 2003-496502P	P	20030820	
US 2004-536341P	P	20040113	
AU 2004-227945	A3	20040402	
EP 2004-758741	A3	20040402	
US 2004-817332	A1	20040402	
WO 2004-US10088	W	20040402	
US 2004-863771	A1	20040607	

OTHER SOURCE(S): MARPAT 141:343543

AB The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary

frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5HT3 antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount Administration of MCI-225 to rat or cat models of overactive bladder caused a significant dose-dependent increase in bladder capacity.

IT 99487-25-9 99487-25-9D, salts
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-HT3 receptor antagonist and noradrenaline reuptake inhibitor combination for treating lower urinary tract disorders)

RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



IT 99487-26-0, MCI-225
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as 5-HT3 antagonist and noradrenaline reuptake inhibitor; 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor combination for treating lower urinary tract disorders)

RN 99487-26-0 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:610068 CAPLUS
DOCUMENT NUMBER: 141:134099
TITLE: Method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor
INVENTOR(S): Landau, Steven B.; Miller, Cheryl L.; Thor, Karl Bruce
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062624	A2	20040729	WO 2004-US809	20040113
WO 2004062624	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204827	A1	20040729	AU 2004-204827	20040113
AU 2004204827	B2	20060629		
CA 2512022	A1	20040729	CA 2004-2512022	20040113
US 20040147510	A1	20040729	US 2004-757981	20040113
EP 1567163	A2	20050831	EP 2004-701830	20040113
EP 1567163	B1	20070411		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006748	A	20051220	BR 2004-6748	20040113
CN 1750827	A	20060322	CN 2004-80004249	20040113
JP 2006516977	T	20060713	JP 2006-500937	20040113
AT 359079	T	20070515	AT 2004-701830	20040113
NZ 541009	A	20070928	NZ 2004-541009	20040113
ES 2285407	T3	20071116	ES 2004-701830	20040113
US 20040254171	A1	20041216	US 2004-846978	20040514
US 20040254172	A1	20041216	US 2004-846979	20040514
US 7094786	B2	20060822		
IN 2005DN02961	A	20070413	IN 2005-DN2961	20050704
MX 2005PA07379	A	20060210	MX 2005-PA7379	20050707
ZA 2005005816	A	20060927	ZA 2005-5816	20050720

PRIORITY APPLN. INFO.: US 2003-440076P P 20030113

US 2003-492478P	P	20030804
US 2004-757981	A1	20040113
WO 2004-US809	W	20040113

OTHER SOURCE(S): MARPAT 141:134099

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount In addition, the method of the invention comprises administering a NARI alone. A pharmaceutical composition comprising: (a) a first amount of a 5-HT3 receptor antagonist; and (b) a second amount of a noradrenaline reuptake inhibitor is also claimed.

IT 99487-25-9 99487-25-9D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating nausea, vomiting, or retching by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610067 CAPLUS
DOCUMENT NUMBER: 141:134098
TITLE: Method of treating functional bowel disorders by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor

INVENTOR(S): Landau, Steven B.
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062623	A2	20040729	WO 2004-US807	20040113
WO 2004062623	A3	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204825	A1	20040729	AU 2004-204825	20040113
AU 2004204825	B2	20070719		
CA 2512983	A1	20040729	CA 2004-2512983	20040113
US 20040147509	A1	20040729	US 2004-757364	20040113
EP 1558081	A2	20050803	EP 2004-701811	20040113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006749	A	20051220	BR 2004-6749	20040113
JP 2006516976	T	20060713	JP 2006-500936	20040113
NZ 541008	A	20070928	NZ 2004-541008	20040113
US 20040254168	A1	20041216	US 2004-838789	20040503
US 20040254169	A1	20041216	US 2004-841317	20040507
US 20040254170	A1	20041216	US 2004-841318	20040507
US 20040259862	A1	20041223	US 2004-841319	20040507
US 20050032780	A1	20050210	US 2004-866593	20040611
US 20050192270	A1	20050901	US 2005-119357	20050429
IN 2005DN02967	A	20070413	IN 2005-DN2967	20050704
MX 2005PA07381	A	20060210	MX 2005-PA7381	20050707
ZA 2005005817	A	20060426	ZA 2005-5817	20050720
US 20060217391	A1	20060928	US 2006-441905	20060526

PRIORITY APPLN. INFO.:		
US 2003-440077P	P	20030113
US 2003-492480P	P	20030804
US 2004-757364	A1	20040113
WO 2004-US807	W	20040113
US 2005-119357	A1	20050429

OTHER SOURCE(S): MARPAT 141:134098

AB The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea. A pharmaceutical composition comprising: (a) a first amount of a 5-HT3 receptor antagonist; and (b) a second amount of a noradrenaline reuptake inhibitor is also claimed.

IT 99487-25-9 99487-25-9D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(method of treating functional bowel disorders by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:203673 CAPLUS
DOCUMENT NUMBER: 140:229481
TITLE: New therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine
INVENTOR(S): Cavalla, David; Gristwood, Robert William
PATENT ASSIGNEE(S): Arachnova Therapeutics Ltd., UK
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019948	A1	20040311	WO 2003-GB3720	20030828

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2496695	A1	20040311	CA 2003-2496695		20030828
AU 2003259373	A1	20040319	AU 2003-259373		20030828
AU 2003259373	B2	20060309			
EP 1539172	A1	20050615	EP 2003-791032		20030828

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003013836	A	20050621	BR 2003-13836		20030828
CN 1678322	A	20051005	CN 2003-820617		20030828
JP 2006500427	T	20060105	JP 2004-569724		20030828
US 20060167005	A1	20060727	US 2005-525532		20050725
PRIORITY APPLN. INFO.:			GB 2002-20064	A	20020829
			GB 2003-16115	A	20030709
			WO 2003-GB3720	W	20030828

AB 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain, and other conditions.

IT 99487-25-9 476148-82-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic uses of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine)

RN 99487-25-9 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)- (CA INDEX NAME)



RN 476148-82-0 CAPLUS
CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, hydrochloride, hydrate (1:1:1) (CA INDEX NAME)



● HCl

● H_2O

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 14:33:28 ON 07 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 14:33:36 ON 07 OCT 2008
L1              STRUCTURE UPLOADED
L2            4 S L1 FULL

     FILE 'MEDLINE, CAPLUS, WPIDS' ENTERED AT 14:34:09 ON 07 OCT 2008
L3           35 S L2
L4            6 S L3 AND (NAUSEA OR VOMIT? OR EMESIS)
L5            0 S L3 AND (CANCER OR TUMOR)
L6            6 S L3 AND CHEMOTHERAP?

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    84.33     262.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -9.60      -9.60

STN INTERNATIONAL LOGOFF AT 14:35:50 ON 07 OCT 2008
```